Damora Therapeutics DMRA
$23.22 −$1.08 (-4.44%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $23.22 0.00%
Open$23.81
Prev close$24.30
Day range$23.13 – $24.51
Volume643.4K
Market cap$1.44B
P/E (TTM)13.6
Dividend yield–
DMRA Stock News
Headlines matching Damora Therapeutics or the DMRA ticker, most recent first.
- Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
- Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $60 Positive
- LifeSci Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $45
- H.C. Wainwright Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $45
- A Quick Look at Today's Ratings for Damora Therapeutics(DMRA.US), With a Forecast Between $40 to $50
- A Quick Look at Today's Ratings for Damora Therapeutics(DMRA.US), With a Forecast Between $40 to $45
- Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $40 Positive
- Jefferies Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $50
- TD Cowen Initiates Damora Therapeutics(DMRA.US) With Buy Rating
- RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
- Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $35
- Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
- TD Cowen Maintains Damora Therapeutics(DMRA.US) With Buy Rating
- H.C. Wainwright Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $45
- Wedbush Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $35
No comments yet — be the first to weigh in on DMRA.
Sign in to join the discussion.